Akhil Padarti
Vascular Neurology · Temple, TXNPI 1518594605
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $578 and has fallen 86.7% since, to $77 in 2025.
Across 74 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$323
- AbbVie$200
- Eisai Inc.$193
- UCB, Inc.$156
- Grifols USA, LLC$78
- W. L. Gore & Associates, Inc.$77
- plus $574 from 15 others
What the payments were for
- Food & beverage$1,601100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $323 |
| AbbVie | 11 | $200 |
| Eisai Inc. | 10 | $193 |
| UCB, Inc. | 7 | $156 |
| Grifols USA, LLC | 2 | $78 |
| W. L. Gore & Associates, Inc. | 1 | $77 |
| Amgen | 4 | $71 |
| Jazz Pharmaceuticals Inc. | 3 | $60 |
| Biogen | 3 | $55 |
| SK Life Science, Inc. | 2 | $50 |
| Novartis | 2 | $49 |
| Tanabe Pharma America, Inc. | 3 | $48 |
| Neurocrine Biosciences, Inc. | 2 | $46 |
| Acadia Pharmaceuticals Inc | 2 | $42 |
| Argenx US, Inc. | 1 | $42 |
| Genentech USA, Inc. | 1 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $20 |
| EMD Serono, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Pfizer | 1 | $15 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$1,601 in reported general payments places this provider in the 55th percentile of 76 vascular neurology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AptiomEslicarbazepine Acetate | 11 | $34,352 |
| Levetiracetam | 26 | $691 |
| Zonisamide | 25 | $678 |
| Donepezil Hcl | 13 | $146 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Temple
- Jennifer Rasmussen-WinklerTemple$7K
- Farzan GhodsianzadehTemple$264
- Dion GraybealTemple$230
- Sarita KambhampatiTemple$127
- Ameer HassanHarlingen$1M
- John VolpiHouston$407K
- Lee BirnbaumSan Antonio$195K
- Amrou SarrajHouston$182K
- Sunil ShethHouston$54K
- Steven WarachAustin$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.